Skip to Content

Conivaptan Dosage

Applies to the following strength(s): 5 mg/mL ; 20 mg/100 mL-D5%

The information at Drugs.com is not a substitute for medical advice. Always consult your doctor or pharmacist.

Usual Adult Dose for:

Additional dosage information:

Usual Adult Dose for SIADH

For hospitalized patients:
loading dose: 20 mg in 100 mL of 5% dextrose intravenously over 30 minutes. The loading dose should be followed by 20 mg in 250 mL of 5% dextrose administered in a continuous intravenous infusion over 24 hours. Following the initial day of treatment, conivaptan is to be administered for an additional 1 to 3 days in a continuous infusion of 20 mg per day. If serum sodium is not rising at the desired rate, conivaptan may be titrated upward to a dose of 40 mg daily administered in a continuous intravenous infusion. The total duration of infusion of conivaptan (after the loading dose) should not exceed four days. .

Usual Adult Dose for Hyponatremia, euvolemic

For hospitalized patients:
loading dose: 20 mg in 100 mL of 5% dextrose intravenously over 30 minutes. The loading dose should be followed by 20 mg in 250 mL of 5% dextrose administered in a continuous intravenous infusion over 24 hours. Following the initial day of treatment, conivaptan is to be administered for an additional 1 to 3 days in a continuous infusion of 20 mg per day. If serum sodium is not rising at the desired rate, conivaptan may be titrated upward to a dose of 40 mg daily administered in a continuous intravenous infusion. The total duration of infusion of conivaptan (after the loading dose) should not exceed four days. .

Renal Dose Adjustments

No clinically relevant increase in exposure was observed in subjects with mild and moderate renal impairment (creatinine clearance 30 to 80 mL/min). No dose adjustment is necessary. Because of the high incidence of infusion site phlebitis (which can reduce vascular access sites) and unlikely benefit, use in patients with severe renal impairment (creatinine clearance less than 30 mL/min) is not recommended.

Liver Dose Adjustments

No clinically relevant increase in exposure was observed in subjects with mild hepatic impairment; therefore no dose adjustment is necessary. The exposure to conivaptan approximately doubles with moderate hepatic impairment. The impact of severe hepatic impairment on the exposure to conivaptan has not been studied.

Precautions

Infusion site reactions are common and can include serious reactions, even with proper infusion rates. Administer via large veins, and rotate the infusion site every 24 hours.

Safety and effectiveness have not been established in pediatric patients (less than 18 years of age).

Dialysis

Data not available

Hide